No Picture
News

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expr… […]

No Picture
News

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expr… […]

No Picture
News

Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFa Antibody for Canine Inflammatory Bowel Disease

SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its mon… […]

No Picture
News

Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine

Novel technology developed by Cleveland Clinic researchers

SAN JOSE, Calif., Dec. 21, 2020 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, anno… […]

No Picture
News

BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

Children Treated with Vosoritide Demonstrate Cumulative Height Gain of 3.52 cm at Year 2 Compared to Untreated ChildrenNo New Safety Signals ObservedCurrent Regulatory Review Timelines on Track

SAN RAFAEL, Calif., Dec. 21, 2020 /PRNewswire/ — BioMar… […]

No Picture
News

Protagonist Therapeutics, Inc. Announces Closing of $115 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEWARK, Calif., Dec. 15, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,476,189 shares of its … […]